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Background: Antibiotic resistant S. aureus infection is a global threat. Newer approaches are required to control
this organism in the current scenario. Cell wall degrading enzymes have been proposed as antibacterial agents for
human therapy. P128 is a novel antistaphylococcal chimeric protein under development against S. aureus for
human use which derives its bacterial cell wall degrading catalytic endopeptidase domain from ORF56, the Phage K
tail-structure associated enzyme. Lead therapeutic entities have to be extensively characterized before they are
assessed in animals for preclinical safety and toxicity. P128 is effective against antibiotic resistant strains as well as
against a panel of isolates of global significance. Its efficacy against S. aureus in vivo has been established in our lab.
Against this background, this study describes the characterization of this protein for its biochemical properties and
other attributes.
Results: We evaluated the requirement or effect of divalent cations and the metal ion chelator, EDTA upon
biological activity of P128. As the protein is intended for therapeutic use, we tested its activity in presence of body
fluids and antibodies specific to P128. For the same reason, we used standard human cell lines to evaluate
cytotoxic effects, if any.
The divalent cations, calcium and magnesium at upto 25 mM and Zinc upto 2.5 mM neither inhibited nor
enhanced P128 activity. Incubation of this protein with EDTA, human serum, plasma and blood also did not alter
the antibacterial properties of the molecule. No inhibitory effect was observed in presence of hyper-immune sera
raised against the protein. Finally, P128 did not show any cytotoxic effect on HEp2 and Vero cells at the highest
concentration (5 mg/mL) tested.
Conclusions: The results presented here throw light on several properties of protein P128. Taken together, these
substantiate the potential of P128 for therapeutic use against S. aureus. Further development of the protein and
conduct of preclinical safety studies in animals is warranted.Background
Current treatment for staphylococcal infections face
multiple challenges including spread of highly virulent
strains in the hospital and community environments.
Novel therapeutic agents and modalities are becoming a
necessity to combat the often invasive infections by
these strains [1,2].* Correspondence: bsriram@gangagen.com
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reproduction in any medium, provided the orIn S. aureus and other Gram-positive bacteria, where
the outer membrane is absent, the multilayered peptido-
glycan or murein, commonly referred to as the cell wall,
represents the limit of the cell. Peptidoglycan is an im-
portant component in these bacteria, conferring strength
and rigidity to the cell, allowing growth and division,
maintaining cell shape, and protecting against osmotic
lysis [3]. The peptidoglycan therefore presents an excel-
lent target for antimicrobial action. Murein degrading
enzymes that are capable of hydrolyzing the various
carbohydrate or protein linkages of the peptidoglycan
layer bring about cell death. Such enzymes are producedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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appropriate sources of such enzymes would be bacterio-
phages, which are viruses that prey on bacteria and have
co-evolved with their host. P128 is a novel chimeric bac-
teriophage derived protein that is under development in
our laboratory for human therapy against antibiotic re-
sistant staphylococci. P128 has shown potent in vitro
bactericidal activity against many staphylococci, includ-
ing methicillin-resistant S. aureus (MRSA) and has been
efficacious as a topical gel in reducing MRSA nasal car-
riage in an animal model [7]. Efficacy of P128 when
administered parenterally, is a key aspect that is cur-
rently under investigation.
Various systemic components and prevailing condi-
tions or microenvironments could potentially impact the
structure, stability, availability and thereby the biological
activity of P128. In case of antibiotics, plasma protein
binding is often associated with a loss in antibacterial ac-
tivity. Loss due to plasma protein binding is shown to be
upto 97% in case of Fusidic acid [8]. This loss is upto
90% for Daptomycin and the Minimum Inhibitory Con-
centration (MIC) of this antibiotic is adversely affected
in the presence of human serum with associated clinical
failures [9]. In case of antimicrobial peptides (AMPs), it
is known that various defensins are partly or completely
antagonized by high salt conditions or the presence of
plasma proteins in vitro [10,11]. It is also known that the
activity of cationic antimicrobial peptides, such as neu-
trophil defensins is influenced by various microenviron-
mental conditions [12].
Cell wall degrading enzymes are of significantly higher
molecular size compared to AMPs. However, they have
to face similar challenges in physiological environments
that could potentially affect protein folding and stability,
or cause inactivation or inhibition of enzymatic activity.
Inorganic ions, especially metal ions such as Ca2+, Mg2+
and Zn2+, have been shown to modulate the activity of
bacterial cell wall degrading enzymes [13,14]. The likeli-
hood of degradation of such proteinaceous antibacterials
by proteases and neutralization by the immune system
[15] cannot be ignored.
Considering the heterogeneity of biological fluids,
understanding the impact of the physiological and bio-
logical components in such complex matrices on the ac-
tivity of P128 would be critical and forms the basis of
this work. Bactericidal activity of P128 is tested under
various conditions including presence of divalent cations
(Ca2+, Mg2+ and Zn2+), EDTA, hyper-immune sera;
human serum; plasma; and whole blood.
A key milestone that lead molecules have to reach, for
further development as drug candidates, is that they
have to be declared ‘safe’ for use [16]. The major chal-
lenge that overrides the potent and broad-spectrum ac-
tivities of many antimicrobial peptides is in fact, thecytotoxicity they may pose [17,18]. The predictive value
of in vitro cytotoxicity tests that reflect ‘basal’ cytotox-
icity or adverse effects on basic functions common to all
cells, is well-recognized [19]. Understandably, such
assays are routinely applied to the evaluation of pharma-
ceutical molecules as part of the drug discovery process.
P128 has been evaluated in the present work for cyto-
toxicity on two mammalian cell lines.
Methods
P128 expression and purification
P128 protein was expressed and purified as described
previously [20].
Bacterial strains
All strains were cultured in Luria Bertani (LB) broth at
37°C on a rotary shaker (200 rpm). MRSA clinical isolate
COL and mupirocin-resistant community-associated
MRSA USA300 were used for the bactericidal activity
assays. Cell culture media were obtained from HiMedia
labs (India).
Bactericidal activity assay
The bactericidal activity of P128 was assessed by a CFU
reduction assay. Briefly, cultures of S. aureus were grown
in LB broth until absorbance at 600 nm (A600) reached
1.0, and then diluted in LB broth to obtain 1x108 cells/ml.
For all assays, 1x108 cells/ml were used, unless other-
wise stated. Cells (~1x107 in 100 μl) were treated with
purified protein at specified concentrations in 100 μl
volume and incubated at 37°C, 200 rpm for 1 h. The
residual viable bacterial cells (colony forming units;
CFUs) were enumerated by serial dilution and plating
on LB agar plates. Dose–response of P128 was evaluated
using this assay with varied cell numbers ranging from
~108 to ~101 cells/ml of S. aureus USA300 treated with
purified P128 in the concentration range of 0.25 –
10 μg/ml.
Effect of divalent cations and EDTA as modulators of
P128 activity
The effect of calcium, magnesium and zinc ions on P128
activity was determined at 37°C in saline, containing dif-
ferent concentrations of Calcium Chloride or Magne-
sium Chloride or Zinc Acetate.
2 μg of purified P128 was incubated in 10, 20, and
50 mM CaCl2 (Sigma, USA) or MgCl2 (HiMedia) at 37°
C for 30 min. Similarly, 2 μg of P128 was incubated in
0.5, 1, 2 and 5 mM Zinc Acetate (Merck, India) at 37°C
for 30 min. This was then tested for bactericidal activity
on S. aureus USA300 as described. The final salt con-
centrations in the assay were 5, 10 and 25 mM of CaCl2
or MgCl2 and 0.25, 0.5, 1 and 2.5 mM Zinc Acetate.
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at 37°C in saline, containing different concentrations of
K2 EDTA. 2 μg of purified P128 was incubated in 1.25,
2.5, 5, 10 and 20 mM K2 EDTA (Merck, India) at 37°C
for 30 min. This was then tested for bactericidal activity
on S. aureus USA300 as described. The final salt con-
centrations in the assay were 0.625, 1.25, 2.5, 5 and
10 mM K2 EDTA.
P128 activity in human plasma, serum and whole blood
Bactericidal activity of P128 on S. aureus was tested in
presence of human biological matrices using the CFU
reduction assay format. To prepare serum, 6 ml of whole
human blood was collected using a pyrogen free syringe
and allowed to clot at ambient temperature. Tubes were
centrifuged at 2300 x g for 5 min and serum collected.
For whole blood, 6 ml of blood was collected and
K2EDTA (Merck, India) was added at a concentration of
1.5 mg/ml. Human plasma was from a commercial
source.
2 μg of purified P128 was diluted into 100 μl plasma,
serum or whole blood from a 1 mg/ml stock (final assay
concentration - 10 μg/ml). 1×107 cells of S. aureus COL
or USA300 were resuspended in 100 μl of plasma, serum
or whole blood (final assay concentration - 5×107 cells/ml)
and treated with P128 that was pre-incubated at ambi-
ent temperature for 20 min in the corresponding
matrix. Cells incubated in serum, plasma or whole
blood without addition of P128 served as controls.
Residual CFU were enumerated at the end of 1 h incu-
bation at 37°C.
Effect of hyper-immune sera on P128 activity
P128-specific antibodies were tested for the ability to
neutralize the activity of P128. New Zealand White rab-
bits were immunized with purified P128 using a stand-
ard protocol comprising a primary immunization with
complete Freund’s adjuvant and three boosts in incom-
plete Freund’s adjuvant. Enzyme-linked immunosorbent
assay (ELISA) titers were>100,000 (reciprocal of the di-
lution of the inflection point in a typical best-fitted sig-
moid curve).
The assay procedure was modified from that described
previously [21]. P128 in 0.85% saline (100 μl) was diluted
from 100 μg/well – 0.09 μg/well through 11 wells in a
microtiter plate. Ten microliters of either hyper-immune
rabbit serum, pre-immune serum, or saline was added to
each well and incubated at 25°C for 15 min. An equal
volume (100 μl) of S. aureus USA300 containing 1x108
cells (final assay concentration - 5x108 cells/ml) was
then added to each well. After 30 min at 25°C, 50 μl
from each assay well was plated out and residual CFU
enumerated. Cells incubated in saline and treated with
P128 prepared in saline served as the control forbiological activity at each test concentration of the pro-
tein in the assay. Cells incubated in saline, pre-immune
or hyper-immune sera without the addition of P128
served as cell controls.
In vitro cytotoxicity of P128
The cytotoxicity of P128 was evaluated on HEp2 and
Vero cell lines, using MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay [22]. HEp2
(ATCC Cat. No.CCL-23, Human epithelial carcinoma)
and Vero (ATCC Cat. No. CCL-81, African monkey kid-
ney) were purchased from National Centre for Cell
Sciences, Pune, India and were maintained in Eagle’s
Minimum Essential Medium (EMEM) (Sigma, USA)
supplemented with 10% Fetal Bovine Serum (European
Grade FBS, Biological Industries, Israel) and 100 U/mL
of ampicillin and 100 μg/mL of streptomycin (Sigma,
USA), in a 37°C incubator (NuAire, USA) under an at-
mosphere of 5% CO2.
Briefly, 1×105 cells were seeded per well in a 96-well
flat-bottom microtitre plate (CellStar, Greiner), in 100
μL of complete growth medium and the plate incubated
at 37°C for 24 h. After 24 h, fresh growth medium was
replenished in the wells. P128 was diluted from an ori-
ginal stock to obtain concentrations ranging from 0.078
to 5 mg/mL, in serum-free EMEM, and 100 μL of each
solution was added to respective wells. A 0.5 mg/mL so-
lution of mitomycin C (Sigma, USA; prepared in
EMEM) was employed as positive control, and cells trea-
ted with 100 μL of EMEM served as negative controls.
Each group was evaluated in quadruplicates and the
whole experiment repeated twice. The cells were incu-
bated with the solutions for a period of 24 h, followed
by removal of the solutions and replenishment of fresh
growth medium. Twenty μL of a stock solution of MTT
(Sigma, 5 mg/mL in double distilled water) was added
per well and the plate incubated in the dark for 4 h at
37°C. This was followed by removal of the contents of
the wells and dissolution of the formazan crystals by
addition of 150 μL/well of dimethyl sulfoxide (Sigma,
USA) solution. Absorbance values at 590 nm were
obtained with the help of a UV–vis spectrophotometer
(TECAN) within 15 min. The percentage cell viability in
each group was calculated in relation to that of the un-
treated control cells.
Data analysis
A minimum of two experiments were performed for
each CFU reduction assay & cytotoxicity assay. Results
were obtained as means and standard deviations. Statis-
tical significance was evaluated by one-way analysis of
variance (ANOVA) followed by Tukey-Kramer Multiple
Comparisons Test wherever appropriate. A value of
P<0.05 was considered to be significant. Statistical
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InStat trial version from GraphPad Software.Results and discussion
It is well-established that biological activity of enzymes
is influenced by various physiological conditions, often
referred to as ‘microenvironments’. Extracellular ions
(e.g., Ca2+, Mg2+, Zn2+) play an important role as modu-
lators of activity of enzymes [23,24]. Maintenance of
structural and functional stability in tissue or fluid com-
partments is therefore critical for therapeutic efficacy.
The aim of this study was to investigate the influence of
various conditions and biological matrices on the bacteri-
cidal activity of P128 preliminary to its consideration for
parenteral use in humans.
The primary criteria for a therapeutic entity are safety
and efficacy, as judged by lack of any form of toxicity
when administered along with desired biological activity.
Cytotoxicity of antimicrobial peptides is one of the main
reasons that prevent the use of this class of molecules as
antibacterial drugs. Even antimicrobial peptides that are
a part of innate immunity are subject to inhibition in
physiological fluids and conditions and show relatively
poor activity or are rapidly inactivated [10-12]. It is im-
perative that molecules of heterologous origin, such as
P128 be thoroughly evaluated for potential effects of
biological matrices and associated microenvironments
on its activity and any form of toxicity the molecule may
present to humans.P128 dose response
In vitro assays have to be carefully designed considering
various factors, to enable results and outcomes to be
extrapolated to other purposes or translated to further
studies. Here, a dose response study was performed,
where P128 was tested against S. aureus in a checker-
board assay, correlating the dose-dependence of P128
with variation in target bacterial cell numbers.
The results indicate that as little as 50 ng of P128 was
able to kill >2 log10 CFU/ml (>99%, p<0.001) of 10
5
cells. However, this dose does not cause significant re-
duction when 106 cells were present in the same volume.
In case of the higher doses tested, 500 ng of P128 was
sufficient to kill >4 log10 CFU/ml (>99.99%, p<0.001)
of 107 cells and 1 μg of P128 reduced 108 cells by >4
log10 CFU/ml (>99.99%, p<0.001). These results estab-
lished the dose dependent bactericidal activity of P128
on S. aureus cells (Figure 1). The optimal protein con-
centration required to effect significant CFU reduction
for a specified range of bacterial cell numbers was
arrived at. The concentrations of P128 to be used for
evaluation of activity under the different test conditions
were judged based on these results.Effect of divalent cations and EDTA as modulators of
P128 activity
It is well known that inorganic ions and salts are capable
of influencing the biological activity of enzymes. The ac-
tivity of several bacteriolytic enzymes is modulated by
different ion species. Bacteriophage endolysin LysH5
shows enhanced activity in the presence of Ca2+ and
Mg2+ [25]. Other reported bacterial cell wall degrading
enzymes have been shown to be dependent on the pres-
ence of Ca2+ or Zn2+ for activity [26,27], or inhibited by
one or other ion species such as Mn2+ [25,28]. Zn2+
dependent bactericidal activity against Gram-positive
bacteria is exhibited by cell wall degrading enzymes, in-
cluding lysostaphin which is a zinc-containing metallo-
protease [29].
Staphylolytic endopeptidases have been evaluated for
EDTA inhibition of activity [30] and lysostaphin has
been reported to be inhibited by EDTA [31].
We tested the effect of calcium, magnesium and zinc
on the bactericidal activity of P128 to study whether
concentrations of these ions would inhibit or enhance
antibacterial activity of P128. All P128 treatments led to
a significant reduction (>3 Delta log10 CFU/ml, >99.9%,
p<0.001) in S. aureus CFU. This activity was maintained
in the absence or presence of millimolar concentrations
of all the three divalent cations. The highest concentra-
tion we tested was 25 mM in case of CaCl2 and MgCl2
and 2.5 mM in case of Zinc Acetate (Figure 2). Irrespect-
ive of the presence of the cation, there was no significant
difference in activity within each assay condition. We
conclude that while none of the ions tested potentiated
the biological activity of P128, there was no loss in bac-
tericidal activity observed. This is encouraging since the
concentrations of ions tested here is higher than present
in the physiological context. To confirm that soluble
magnesium, calcium or zinc is not essential for enzym-
atic activity of P128, we tested the effect of EDTA, which
is an ion-chelator and used to inhibit cation-dependent
enzymes. There was a significant reduction (>4 Delta
log10 CFU/ml, >99.99%, p<0.001) in CFU (Figure 2) in
the presence of millimolar concentrations of EDTA
(upto 10 mM) showing no loss of activity.
P128 activity in human plasma, serum and whole blood
We studied the bactericidal activity of P128 in biological
fluids in an attempt to simulate the milieu in which
P128 could encounter the pathogen in vivo. Strong anti-
microbial activities in artificial media or buffer systems
in vitro may not be reproducible in complex fluid matri-
ces such as whole blood, plasma, and serum that contain
multifactorial components [32]. Additionally, whole
blood and other fluid biomatrices may contain pepti-
dases which could potentially degrade proteinaceous
molecules, such as P128. The lethal outcome of a
Figure 1 P128 Dose Response. Biological activity of P128 at different protein concentrations was correlated with varied target cell numbers.
P128 in the range 0.25 μg/ml – 10 μg/ml was added to S. aureus cells taken in the range of 5×101 – 5×108 cells/ml. Bactericidal activity was
assessed by the CFU-reduction assay. This was evaluated in duplicates and the experiment performed twice. Results are expressed as mean
residual CFU/ml±standard deviation.
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occurrence of osmotic lysis when patches of the cell wall
are broken down [33]. Complex matrices such as blood
may provide osmotically stable environments which
could prevent bacterial cell lysis. Such conditions could
favor target pathogenic bacteria and thereby reduce their
susceptibility to P128. Human sera has been previously
reported to have an antagonizing effect on the antibac-
terial activity of lysostaphin [34]. On the other hand, it is
also reported that blood and blood fractions may contain
components that complement or potentiate the action
of antimicrobial agents resulting in amplified pathogen
killing [35].Figure 2 Effect of divalent cations and EDTA as modulators of P128 a
in concentrations of upto 50 mM of CaCl2 or MgCl2; 5 mM Zinc Acetate; 20
concentrations in the assay were 25 mM of CaCl2 or MgCl2; 2.5 mM Zinc A
presence of millimolar concentrations of EDTA or divalent cations; Ca2+, Mg
performed thrice. Results are expressed as mean residual CFU/ml±standardBased in part on these concepts, we evaluated the anti-
staphylococcal activity of P128 in blood and blood
fractions.
Interestingly, no inhibitory effect was observed on
P128 activity under the test conditions due to the com-
ponents in any of these biological fluids. There was some
antimicrobial effect observed in the case of S. aureus
USA300 treated with whole blood. However, this did not
potentiate the antibacterial activity of P128. P128
reduced staphylococcal CFU by >2 log10 CFU/ml
(>99%, p<0.01) in serum, plasma and blood, which was
comparable to the reduction seen in saline, which was
used as a control matrix (Figure 3). No lysis of red bloodctivity. 2 μg of P128 (10 μg/ml) was pre-incubated at 37°C for 30 min
mM K2 EDTA before being tested on S. aureus cells. The final
cetate; 10 mM K2 EDTA. P128 was lethal to S. aureus cells in the
2+ and Zn2+. This was evaluated in duplicates and the experiment
deviation.
Figure 3 Activity of P128 in biological matrices. P128 demonstrates potent bactericidal effects against MRSA clinical isolates (A) COL and (B)
USA300 in the presence of human biological matrices - whole blood, plasma and serum. Both experiments were performed twice. Results are
expressed as mean residual CFU/ml±standard deviation.
Figure 4 Effect of hyper-immune sera on P128 activity. P128 was exposed at varying concentrations to hyper-immune serum and tested for
biological activity against 108 cells of MRSA USA300 in the continued presence of the serum. The experiment was performed twice. Results are
expressed as mean residual CFU/ml±standard deviation.
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sence of erythrolytic toxicity.
This favorable behavior of P128 under the tested con-
ditions is of direct relevance to the potential therapeutic
applications of the protein.
Effect of hyper-immune sera on P128 activity
One of the potential challenges to the use of heterologous
antibacterial proteins for therapy is elicitation of humoral
immune response which could reduce or completely
block its antibacterial activity, especially if to be adminis-
tered repeatedly in the course of treatment. However,
only a fraction of the antibodies elicited by a complexFigure 5 In vitro cytotoxicity of P128. Cytotoxicity of P128 was evaluated
C was used as a control cytotoxic agent and absorbance at 590 nm was in
case of the Mitomycin C or P128-treated groups was based on the cell-con
was evaluated in quadruplicates and the whole experiment repeated twicemacromolecular immunogen which possesses biological
activity is likely to be directly involved in the neutralizing
of that activity. The inhibitory antibodies would be those
directed against a limited number of antigenic epitopes
localized within the catalytic site or the biologically active
conformation of the protein. Sera with high antibody titers
(Ab titer of 10240) to lysostaphin were able to neutralize
lysostaphin activity in vitro [21]. The effect of hyper-
immune serum is reported with other phage derived anti-
bacterial proteins without loss of antibacterial activity
[36,37]. However, even if an inhibitory effect had occurred,
it would have been overcome by the high concentration of
protein that was used in these studies.on mammalian cell lines (A) Vero cells and (B) HEp2 cells. Mitomycin
terpreted as a function of cell viability. Calculation of viable cells in
trol and taking viability in the control group to be 100%. Each group
. Results are expressed as means±standard deviation.
George et al. BMC Research Notes 2012, 5:280 Page 8 of 9
http://www.biomedcentral.com/1756-0500/5/280In this work, we used hyper-immune sera raised
against P128 in rabbits and evaluated the effect of the
sera on the bactericidal activity of P128.
The ELISA titre of P128 antibody was >1:100,000
(data not shown). As seen in Figure 4, a minimum con-
centration of 3.9 μg/ml of P128 reduced cell numbers of
S. aureus USA300 by >1 log10 CFU/ml (>90%, p< 0.05)
in case of both pre-immune sera and saline. This corre-
lated with the retention of activity of P128 in normal
rabbit serum. In case of hyper-immune sera, the min-
imum concentration of P128 required for >2 log10
CFU/ml reduction in viable cells was 2-fold higher than
for pre-immune sera, which we do not consider to be of
significance in this immune-assay format. Therefore,
P128 retained activity in saline, pre-immune sera or
hyper-immune sera. The high affinity and rapid binding
of P128 to the staphylococcal peptidoglycan could be
responsible for the lack of inhibition by antibodies,
which is very encouraging in the view of its proposed
use against systemic infection.
In vitro cytotoxicity of P128
Antimicrobial peptides and proteins are known to be a
part of the innate defense system in humans [38]. Often
many of these, show optimal antimicrobial functions
only if their distribution is restricted to specific environ-
ments and under such conditions, host toxicity is also
minimized [39]. It has been shown that changes in meta-
bolic activity are better indicators of early cell injury.
Use of respiratory indicator dye MTT to measure mito-
chondrial activity as an indicator of metabolic function
is a simple method that is accepted as a routine cytotox-
icity test [40]. In the course of development of P128 as
an antistaphylococcal drug for human use, P128 was
tested on one normal cell line, Vero and a carcinoma cell
line, HEp2 (Figure 5). Cells were treated with P128 in
the range from 0.039 mg/ml to 2.5 mg/ml using the
MTT colorimetric assay. Mitomycin C, used as control
toxic agent at 0.25 mg/ml reduced the number of viable
cells to less than 20% (p< 0.05) in both cell lines. P128
was found to be non-toxic to both HEp2 and Vero cells
up to the highest concentration of 2.5 mg/ml tested.
Typically, the concentration of test agent that reduces
cell viability to 50%, referred to as CC50 or 50% cytotoxic
concentration is calculated in comparison to control
cells. For P128, no reduction in viability of cells could be
observed at the highest concentration tested, which is
2.5 mg/ml and which corresponds to more than 100
times the MIC of this protein for most S. aureus isolates
[20]. Therefore, absence of in vitro cytotoxicity as tested
on immortalized somatic cells can be accepted as an
early indicator of safety of P128, paving the way for fur-
ther characterization and preclinical safety/toxicity stud-
ies in animals.Conclusions
P128 exerts potent and remarkably durable antimicrobial
activity as evidenced by comparable bactericidal activity
in conventional artificial matrices, such as buffers and
saline and in complex matrices or biological fluids in-
cluding whole blood, plasma and normal and hyper-
immune sera.
The antistaphylococcal activity of P128 was not influ-
enced by the presence of divalent cations, Ca2+, Mg2+ or
Zn2+ & EDTA.
The protein retains its antistaphylococcal, bactericidal
activity under physiological conditions that are likely to
be relevant to its therapeutic use in vivo. P128 did not
show any cytotoxic effects on mammalian cells.
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